Mark A. Socinski, MD - Expanding Options and Difficult Choices in the Initial Treatment of Advanced NSCLC: How to Personalize Treatment Decisions in the Era of Immuno-Oncology and Combinations

50:48
 
Share
 

Manage episode 231042467 series 9912
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.
Go online to PeerView.com/JYT860 to view the entire program with slides. In this activity, experts in lung cancer review the current recommendations for predictive testing to guide therapeutic decisions for patients with advanced non–small cell lung cancer (NSCLC), analyze the evidence supporting the use of rational approaches with immunotherapies, including combinations of immune checkpoint inhibitors with chemotherapies and other agents, and discuss the practical considerations for selecting the best therapeutic option for each patient with advanced NSCLC who doesn’t have a targetable mutation or molecular alteration. Upon completion of this activity, participants will be able to: Evaluate the efficacy/safety profiles and clinical roles of approved and investigational therapies and combinatorial approaches used in the frontline setting for advanced-stage driver mutation–negative NSCLC, Discuss the role of biomarkers (PD-L1 expression, tumor mutational burden) and other tumor-, patient-, and treatment-related considerations that may influence treatment selection for these patients, Implement individualized, evidence-based, patient-centric first-line treatment plans for patients with advanced NSCLC.

261 episodes available. A new episode about every 3 days averaging 58 mins duration .